Phase II Study of Bryostatin 1 in Patients with Relapsed Multiple Myeloma
- 1 August 2001
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 19 (3) , 245-247
- https://doi.org/10.1023/a:1010676719178
Abstract
Bryostatin 1, a macrocyclic lactoneisolated from the marine bryozoan Bugula neritina,is a protein kinase C (PKC) modulator which has shown bothpreclinical and clinical activity inlymphoid...Keywords
This publication has 8 references indexed in Scilit:
- Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.2000
- Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.1998
- Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.Journal of Clinical Oncology, 1998
- Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphomaLeukemia Research, 1995
- The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphomaAnti-Cancer Drugs, 1995
- Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.1994
- Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.Proceedings of the National Academy of Sciences, 1986
- Isolation and structure of bryostatin 1Journal of the American Chemical Society, 1982